Expansion of plasma centers is strengthening the Hepagam B Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Hepagam B Market At The End Of The 2026–2030 Forecast Period?

The expansion observed historically stemmed from factors such as the worldwide prevalence of hepatitis B, the recognized significance of immune globulins, the implementation by hospitals for managing exposures, deficiencies within vaccination programs, and the dangers of occupational exposure.

Growth anticipated during the forecast period is attributable to the reinforcement of public health policies, enhanced safety measures for healthcare workers, the expansion of screening programs, an increase in hospital-based prophylaxis, and worldwide initiatives for hepatitis elimination.

Key trends observed in the forecast period include a heightened demand for post-exposure prophylaxis, a greater emphasis on maternal and neonatal protection, the broader application of immunoglobulin therapies, increasing awareness about hepatitis B prevention, and refined infection control protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20079&type=smp

Which Market Drivers Are Supporting The Expansion Of The Hepagam B Market?

The expanding occurrence of hepatitis B is anticipated to stimulate the expansion of the hepagam B market. Hepatitis B infections are liver diseases resulting from the hepatitis B virus (HBV), which can progress to chronic illness, cirrhosis, or liver cancer. The rise in these infections is attributed to insufficient vaccination, heightened spread among vulnerable groups, and limited knowledge of preventative strategies. HepaGam B works to prevent hepatitis B infection by granting passive immunity to those exposed to the virus. For example, in April 2024, the World Health Organization, an intergovernmental organization based in Switzerland, reported that roughly 254 million people globally were living with chronic hepatitis B infection in 2022, with 1.2 million new cases identified annually. This condition resulted in approximately 1.1 million deaths, mainly from cirrhosis and hepatocellular carcinoma (primary liver cancer). Consequently, the growing prevalence of Hepatitis B will act as a significant driver for the hepagam B market. The rise in healthcare expenditure is anticipated to quicken the expansion of the hepagam B market. Healthcare spending is climbing due to elements like a growing elderly population, the increasing occurrence of chronic illnesses, innovations in medical technology, and a greater need for superior care. Elevated healthcare spending benefits hepagam B by facilitating more significant investment in preventative therapies, improving availability of immunoglobulin treatments, and enhancing the handling of hepatitis B-related issues. For example, in April 2024, the World Health Organization, a government department located in Switzerland, stated that worldwide health strategies seek to ensure 80% of individuals with chronic hepatitis B and C infections receive treatment by 2030. Thus, the escalating healthcare spending will propel the growth of the hepagam B market.

What Segment Types Make Up The Hepagam B Market?

The hepagam b market covered in this report is segmented –

1) By Product Type: Immunoglobulin Preparations, Vaccines, Antiviral Therapies

2) By Indication: Post-Exposure Prophylaxis, Chronic Hepatitis B Treatment

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Market Trends Are Creating New Opportunities In The Hepagam B Market?

A significant trend in the hepagam B market involves an emphasis on expanding plasma collection centers to secure a competitive advantage within the industry. Plasma collection refers to the process where plasma is taken from a donor’s blood, subsequently utilized in diverse medical treatments, including the creation of immunoglobulins and therapies for clotting factors. As an illustration, in September 2024, Kamada Limited, an Israel-based biopharmaceutical firm, announced the inauguration of a new plasma collection facility located in Houston, Texas, with the goal of improving its specialized plasma collection activities. This facility, spanning 12,000 square foot, is anticipated to accommodate more than 50 donor beds and achieve an annual collection volume of around 50,000 liters. The center will concentrate on gathering both normal source plasma and specialty plasma, projected to contribute an estimated $8 million to $10 million in yearly revenue when fully operational. This expansion is consistent with Kamada’s overarching strategy to become a prominent global entity in the market for specialty plasma-derived products.

Who Are The Key Players Driving Competition In The Hepagam B Market?

Major companies operating in the hepagam b market are Kamada Ltd., Kibiopharma Inc., Emergent BioSolutions Inc.

Read the full hepagam b market report here:

https://www.thebusinessresearchcompany.com/report/hepagam-b-global-market-report

How Is The Hepagam B Market Distributed Across Key Geographic Regions?

North America was the largest region in the hepagam B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepagam b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Hepagam B Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20079&type=smp

Browse Through More Reports Similar to the Global Hepagam B Market 2026, By The Business Research Company

Hepatorenal Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report

Chronic Hepatitis B Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Hexane Market Report 2026

https://www.thebusinessresearchcompany.com/report/hexane-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795